title: Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.
abstract: The 5thBiennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th- 8thMay in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.
authors.affiliation: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; The George Pantziarka TP53 Trust, London, UK.
authors.forename: Pan
authors.initials: P
authors.lastname: Pantziarka
authors.affiliation: Nature Reviews Clinical Oncology, London N1 9XW, UK.
authors.forename: Lisa
authors.initials: L
authors.lastname: Hutchinson
authors.affiliation: Service d'hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants, AP-HM, Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille, France; Metronomics Global Health Initiative, Marseille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: André
authors.affiliation: Inria team MONC and Institut de Mathématiques de Bordeaux, Talence, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Benzekry
authors.affiliation: European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertolini
authors.affiliation: Malabar Cancer Centre, Thalassery, India.
authors.forename: Atanu
authors.initials: A
authors.lastname: Bhattacharjee
authors.affiliation: ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
authors.forename: Shubhada
authors.initials: S
authors.lastname: Chiplunkar
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
authors.affiliation: ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
authors.forename: Vikram
authors.initials: V
authors.lastname: Gota
authors.affiliation: ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
authors.forename: Sudeep
authors.initials: S
authors.lastname: Gupta
authors.affiliation: Tata Memorial Hospital, Mumbai, India.
authors.forename: Amit
authors.initials: A
authors.lastname: Joshi
authors.affiliation: ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
authors.forename: Sadhana
authors.initials: S
authors.lastname: Kannan
authors.affiliation: Biological Sciences Platform, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Kerbel
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Kieran
authors.affiliation: Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Palazzo
authors.affiliation: PRA Health Sciences, Mumbai, India.
authors.forename: Aparna
authors.initials: A
authors.lastname: Parikh
authors.affiliation: INSERM UMR 911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, Aix-Marseille University, Marseille, France; Metronomics Global Health Initiative, Marseille, France.
authors.forename: Eddy
authors.initials: E
authors.lastname: Pasquier
authors.affiliation: Tata Memorial Hospital, Mumbai, India.
authors.forename: Vijay
authors.initials: V
authors.lastname: Patil
authors.affiliation: Tata Memorial Hospital, Mumbai, India.
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
authors.affiliation: Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
authors.forename: Yuval
authors.initials: Y
authors.lastname: Shaked
authors.affiliation: Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
authors.forename: Giselle Saulnier
authors.initials: GS
authors.lastname: Sholler
authors.affiliation: Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital and RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Sterba
authors.affiliation: Department of Biology, Boston University, Boston, MA 02215, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Waxman
authors.affiliation: Tata Memorial Hospital, Mumbai, India; Metronomics Global Health Initiative, Marseille, France.
authors.forename: Shripad
authors.initials: S
authors.lastname: Banavali
keywords: LMIC; Metronomic chemotherapy; anti-angiogenics; cancer; drug repurposing